118 related articles for article (PubMed ID: 37341435)
1. TACC3 is an independent prognostic marker, and knockdown of TACC3 enhances the efficacy of CDK1 inhibitor RO3306 in liver cancer cells.
Guo E; Yang J; Li L; Chen J; Liu H
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23402. PubMed ID: 37341435
[TBL] [Abstract][Full Text] [Related]
2. TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma.
Zhou DS; Wang HB; Zhou ZG; Zhang YJ; Zhong Q; Xu L; Huang YH; Yeung SC; Chen MS; Zeng MS
Oncotarget; 2015 Sep; 6(27):24163-77. PubMed ID: 26219398
[TBL] [Abstract][Full Text] [Related]
3. Transforming acidic coiled-coil-containing protein 3 (TACC3) overexpression in hepatocellular carcinomas is associated with "stemness" and epithelial-mesenchymal transition-related marker expression and a poor prognosis.
Nahm JH; Kim H; Lee H; Cho JY; Choi YR; Yoon YS; Han HS; Park YN
Tumour Biol; 2016 Jan; 37(1):393-403. PubMed ID: 26219896
[TBL] [Abstract][Full Text] [Related]
4. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
Wu CX; Wang XQ; Chok SH; Man K; Tsang SHY; Chan ACY; Ma KW; Xia W; Cheung TT
Theranostics; 2018; 8(14):3737-3750. PubMed ID: 30083256
[No Abstract] [Full Text] [Related]
5. Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1.
Dang XW; Pan Q; Lin ZH; Wang HH; Li LH; Li L; Shen DQ; Wang PJ
Aging (Albany NY); 2021 May; 13(16):20094-20115. PubMed ID: 34032605
[TBL] [Abstract][Full Text] [Related]
6. ASRGL1 downregulation suppresses hepatocellular carcinoma tumorigenesis in a CDK1-dependent manner.
Wang X; Wang Y; Yang L; Yuan J; Shen W; Zhang W; Wang J; Tao K
Dig Liver Dis; 2023 Jul; 55(7):955-966. PubMed ID: 36572570
[TBL] [Abstract][Full Text] [Related]
7. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells.
Wu Q; Qin SK; Teng FM; Chen CJ; Wang R
J Hematol Oncol; 2010 Oct; 3():43. PubMed ID: 21034513
[TBL] [Abstract][Full Text] [Related]
8. Exportin-T promotes tumor proliferation and invasion in hepatocellular carcinoma.
Lin J; Hou Y; Huang S; Wang Z; Sun C; Wang Z; He X; Tam NL; Wu C; Wu L
Mol Carcinog; 2019 Feb; 58(2):293-304. PubMed ID: 30334580
[TBL] [Abstract][Full Text] [Related]
9. Immature colon carcinoma transcript-1 promotes cell growth of hepatocellular carcinoma via facilitating cell cycle progression and apoptosis resistance.
Chang W; Yu Z; Tian M; Lin X
Oncol Rep; 2017 Dec; 38(6):3489-3496. PubMed ID: 29130100
[TBL] [Abstract][Full Text] [Related]
10. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
Li L; Huang K; Zhao H; Chen B; Ye Q; Yue J
Cell Cycle; 2020 May; 19(10):1236-1252. PubMed ID: 32275843
[TBL] [Abstract][Full Text] [Related]
11. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties.
Cai J; Li B; Zhu Y; Fang X; Zhu M; Wang M; Liu S; Jiang X; Zheng J; Zhang X; Chen P
EBioMedicine; 2017 May; 19():18-30. PubMed ID: 28434945
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer.
Shi S; Guo D; Ye L; Li T; Fei Q; Lin M; Yu X; Jin K; Wu W
Cell Death Dis; 2023 Nov; 14(11):778. PubMed ID: 38012214
[TBL] [Abstract][Full Text] [Related]
15. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
16. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermia enhances 17-DMAG efficacy in hepatocellular carcinoma cells with aggravated DNA damage and impaired G2/M transition.
Huang Z; Zhou X; He Y; Ke X; Wen Y; Zou F; Chen X
Sci Rep; 2016 Dec; 6():38072. PubMed ID: 27909289
[TBL] [Abstract][Full Text] [Related]
18. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
20. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
